Navigation Links
Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Date:3/19/2008

- Additional data presentation on picoplatin overcoming platinum resistance

in small cell lung cancer -

SOUTH SAN FRANCISCO, Calif., March 19 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that preliminary data from a Phase 1 trial of an oral formulation of picoplatin in patients with solid tumors will be presented at the 2008 American Association for Cancer Research meeting to be held from April 12-16 in San Diego, CA. In addition, preclinical data of picoplatin overcoming platinum resistant small cell lung cancer cells in platinum resistant cell lines will also be presented at a separate poster presentation.

Details are as follows:

-- A Phase 1 randomized crossover picoplatin bioavailability

pharmacokinetics and pharmacodynamics study.

Abstract #209, Session ID: Clinical Research 1;

Yee L, Sharma S, Breitz H, Karlin D, Phillips A, Houston S, Saleh M.

General Poster Session Sunday April 13, 8:00 AM PT.

-- Picoplatin overcomes resistance in small cell lung cancer cell lines

treated with other platinum-based chemotherapeutics.

Abstract #713, Session ID: Experimental Molecular Therapeutics 3;

Parham C, Shocron E, McMahon G, Patel N.

General Poster Session Sunday April 13, 8:00 AM PT.

Picoplatin is the Company's lead product candidate under investigation in three clinical trials.

About Picoplatin

Picoplatin is a chemotherapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- Research and Markets  has announced the addition ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... monitor, and assess medical conditions, diseases, or infections usually ... earlier and more targeted treatment. These tests are minimally ... This kind of diagnostics provides early detection of diseases ...
(Date:7/22/2014)... , July 22, 2014 BiologicTx ® ... first 3-way Kidney Paired Donation transplant exchange ... procedures happened on July 9 at the Miami Transplant ... Miami, Fla. Kidney Paired ... are not compatible for kidney transplant with one another ...
(Date:7/22/2014)... , July 22, 2014  A central ... a SynCardia temporary Total Artificial Heart ... Strong Memorial Hospital with the Freedom® portable driver ... Fontana, a 64-year-old retiree from a Syracuse ... He managed the condition with medications, an implantable ...
Breaking Medicine Technology:Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 2Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 3BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3
... Calif., Feb. 24, 2011 Codexis, Inc. (Nasdaq: ... promoted to Chief Technology Officer and Senior Vice President, Process ... report to Alan Shaw, Ph.D., President and Chief Executive Officer. ... a 25-year career with DuPont. He served as Vice President, ...
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ) ... ended December 31, 2010. For the fourth quarter ... $227 million and income from continuing operations of $17.6 million, ... million charge related to the settlement of litigation and changes ...
Cached Medicine Technology:Codexis Names David Anton CTO & SVP, Process Development & Manufacturing 2Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010 2Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010 3Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010 4Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010 5Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010 6Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010 7Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010 8Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010 9Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010 10
(Date:7/22/2014)... By Steven Reinberg ... -- Simple blood tests may one day help predict survival ... lateral sclerosis (ALS), also called Lou Gehrig,s disease, Italian researchers ... yield clues to how fast ALS is progressing are called ... kidney and liver health, according to the U.S. National Library ...
(Date:7/22/2014)... (Boston)-- Researchers from Boston University School of Medicine ... that participants who received care through BMC,s Violence ... physical, mental, emotional and social needs of violently ... injuries and experienced life changing behaviors through connections ... feel trust and hope. These findings are reported ...
(Date:7/22/2014)... European Bio stimulants Market report defines and segments the ... of revenue. The bio stimulants market in Europe is ... to $940.6 million by 2018, at a CAGR of ... TOC of the Europe Bio stimulants Market report, to ... http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html , Agriculture contributes to 10% of ...
(Date:7/22/2014)... In a special day of pampering ... School of Beauty joined forces with The Discovery ... a free “Make-over Day.” In a win-win event, Marinello ... the community, and The Discovery House clients had a ... some first-hand experience about career possibilities. , “The ...
(Date:7/22/2014)... 22, 2014 Expert Publishing ... Services , announces the launch of PoisonEXPERT™ ... and safety professionals employed by organizations that use ... to manage the impact of chemicals on their ... to relevant chemical-specific information and medical protocols that ...
Breaking Medicine News(10 mins):Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 2Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 3Health News:Clients of BMC's violence interventional advocacy program find experience supportive 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 2Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 3Health News:PoisonEXPERT™ from ExPub Now Available 2Health News:PoisonEXPERT™ from ExPub Now Available 3
... turning their backs on tanning amid growing concerns over skin ... survey shows that teenagers are resisting the urge to tan ... 5,073 Australian adults and 699 Australian teenagers aged 12 to ... that 68 % of those aged 12-17 said they had ...
... University have found a new model that shows how ... in the presence of microenvironment of tumor cells. // ... skin cell to malignant cell is understood with the ... offer new insights into the influence of the tumor ...
... the developing fetus, a womb confers safety and security to ... a womb is even necessary for normal brain development. // ... found to have a poor brain development when compared to ... done regarding brain development of babies born around 26 weeks ...
... bottle-feeding may impose an increased risk of iron deficiency ... American children) according to // a new study by ... Wisconsin. , ,"This is the first study that ... prolonged bottle-feeding and iron deficiency, among a nationally representative ...
... in the UK has revealed that smokers are unconcerned with ... particular they seemed to be aware of the damage // ... lip and even the teeth, but were strangely reluctant to ... oral and maxillofacial surgeons, who are launching a massive awareness ...
... across the walls of a patient's room have been ... hypertension and rheumatic complaints, a study says.//,A study group ... kept in medicated rooms were cured in shorter less ... study involved 36 patients, of whom 19 were kept ...
Cached Medicine News:Health News:Aussie teens applauded for declining sun tan 2Health News:New Model for understanding Tumor Metastasis 2Health News:Brain development compromised in premature babies 2Health News:Iron deficiency found in children with prolonged bottle feeding 2Health News:Now medicated coir to cure ailments 2
Agarose L03 is recommended for separations of DNA fragments = 1,000 bp....
... Anion traces: chloride (Cl) ≤ 5000 mg/kg sulfate (SO ... 50 mg/kg Cd ≤ 5 mg/kg Co ≤ 5 ... Fe ≤ 10 mg/kg K ≤ 50 mg/kg Mg ... 2000 mg/kg Ni ≤ 5 mg/kg Pb ≤ 5 ...
... ≤ 5000 mg/kg sulfate (SO 4 ) ≤ 5000 ... 5 mg/kg Co ≤ 5 mg/kg Cr ≤ 5 ... K ≤ 50 mg/kg Mg ≤ 5 mg/kg Mn ... 5 mg/kg Pb ≤ 5 mg/kg Zn ≤ 5 ...
... flexible gels for separation of ... of wide range and standard ... mg/mL, clear, faintly yellow, hot ... MP: 90 °C (1% in ...
Medicine Products: